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oFor 18 of the past 20 years, I have sat in the audience
and listened to every American Venous Forum (AVF) Pres-
idential Address. The majority of the addresses were well
written, thoughtful, inspiring, and captivating. As a mem-
ber sitting in the audience, I listened intently, hoping to
glean some pearls of wisdom from the men and women
who had the privilege of being president of this great
organization. I asked myself if given the opportunity, what
would I say when standing at this podium? I have asked
myself this question countless times this year and had
difficulty deciding on a topic. A presidential address is the
one time in an academician’s or practitioner’s career where
a presentation is not based on one’s personal research. No
data were gathered, no statistical analysis occurred, and the
validity of my conclusions cannot be debated based on
the flaws of my scientific design. A presidential address is
the one time where you can share your life’s experiences
and openly discuss personal perspectives. I therefore spoke
to previous past presidents and asked them how they chose
their topics. One past president from the Society for Vas-
cular Surgery (SVS) told me to write my conclusions first
and work backward. The AVF past presidents told me to
discuss my passions in life and share this with the audience.
I therefore asked myself what are my passions in life? The
answer I gave myself was that I am passionate about my
wife and children, I love resident education, I love golf and
the NY Giants despite their poor performance this year, I
love my cultural heritage, and I love the American Venous
Forum.
I did not think an exposition on my family, resident
education, golf, or football would make a good presenta-
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pecifically, I wanted to explore why I loved this organiza-
ion so much. I have been a member of almost every local,
egional, and national general and vascular surgery society
n America, yet the AVF is the only group that I have
edicated a significant amount of my personal and profes-
ional time to. Tom Wakefield, one of our past presidents,
nce said to me “Peter, the AVF is where my heart is” and
n an emotional level, I knew exactly how he felt and what
e meant. I think it is important to expand on why I feel the
ame way. What is it about the culture of this group that
nspires me, motivates me, and makes me want to continue
o contribute? Major corporations ask themselves this very
ame question because they know that corporate values
efine their company, how they are viewed by the rest of the
orld, and the degree to which they are successful organi-
ations. I therefore thought it would be valuable to define
he AVF’s corporate/societal values for the next generation
f leaders and AVF members sitting in the audience today.
hese values are the foundation and perspectives we draw
pon to guide us through changing and often difficult
imes. After defining these values, I will suggest howwe can
pply our guiding principles and draw upon the lessons
earned by the ancient Greeks to address today’s future
hallenges.
So what are our corporate values? I think the values that
est define the AVF are mentorship, tolerance, passion,
nnovation and integrity, and vision and leadership.
ENTORSHIP
My first exposure with the AVF was in 1991. I was a
ourth-year general surgery resident and I was presenting at
y first national meeting. That meeting was memorable for
everal reasons. First, the invited reviewer of my paper, Dr
alph DePalma, left the questions he was going to ask me
t the hotel registration desk so that I would not be nervous
nd overwhelmed at the podium. I never forgot this gesture
nd always made it a practice of mine to do the same when
sked to review a paper. Second, at that meeting, an an-
ouncement wasmade that theNorth American Symptom-
tic Carotid Endarterectomy Trial (NASCET) was termi-
ated by the Data Safety Monitoring Board due to the
verwhelming advantage of carotid endarterectomy for
ymptomatic carotid disease compared with medical ther-
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energy in the meeting hall was palpable. Third, I met my
future vascular surgery mentor, Dr Robert W. Hobson, II.
He was the Recorder that year and in those days, you had to
hand your manuscript in at the meeting. I was struck by his
charisma, charm, and grace, and I remember the impres-
sion he made on me that day. Finally, I met Dr Michael
Hume, the president elect of the AVF that year. He was the
moderator of the session where my paper was presented,
and he took the time to personally seek me out and com-
plement me on my research. I was overwhelmed at the
collegiality of the membership, the enthusiasm of the pre-
senters, and the approachability of the organization’s lead-
ership. The fact that the reviewer of my paper and the
president-elect of the AVF sought me out made me feel
valuable. Without realizing it, the bar for my future na-
tional meeting experiences and expectations was set very
high. The comfortable size of the organization, the intense
effort to elevate the field of venous disease research, and the
desire to encourage young people to choose venous disease
as an academic career opportunity, fostered a mentorship
environment that exists to this day. Registrants to this
meeting, regardless of status, age, or position, can stop an
AVF leader in the corridor and discuss a patient care prob-
lem or a research question without fear of being ignored or
demeaned. The leadership’s approachability, sincerity, and
desire to impassion physicians who care for venous disease
patients supersedes any desire for personal gain or career
advancement.
TOLERANCE
The intense desire to improve the care of a patient’s
suffering from venous disorders is further exemplified by
the organization’s valuation of tolerance. When the orga-
nization was first founded in 1988, the active membership
was limited to 300 people with academic backgrounds. The
goal of the organization at that time was to establish a
forum for the exchange of scientific data, elevate the quality
of venous disease research, and develop the next generation
of venous disease leaders. Over the past 20 years, I think it
is safe to say the organization has achieved its original goals.
Venous disease practitioners are no longer viewed as second
class citizens in the vascular surgery or medical community.
Our national meeting is the pre-eminent national and
international forum for the presentation of cutting-edge
research and a new generation of venous disease leaders has
stepped forward. As part of the natural maturation and
growth of any society, the goals of the organization have
changed. The AVF is no longer an elitist group of acade-
micians, and the society no longer has an exclusive mem-
bership policy. Changes to the organization’s mission, op-
erational structure, and national meeting format have all
occurred with little to no resistance from the leadership.
The willingness and tolerance of the leadership to listen to
the ideas of younger leaders and allow them to implement
their suggestions for change is a phenomenon I have yet to
witness in other academic societies. I am a clear example of
the organization’s tolerance. I was allowed to change the mVF’s membership policy and experiment with the annual
eeting format when I was program director. Most impor-
antly, the leadership tolerated my youthful indiscretions
nd valued my desire to have the organization achieve its
otential. The AVF’s tolerance of people from various
rofessional, cultural, and ethnic backgrounds, fosters in-
lusiveness and an environment conducive to experimenta-
ion and change.
ASSION
Our founding fathers created the American Venous
orum based on their passion for venous disorders and
heir intense desire to improve the well-being of patients
uffering from venous diseases. Just look at the person
itting next to you. If you all were not passionate about
enous disease, none of you would have taken time away
rom your busy practices and paid money to attend this
eeting. Look at our past and present leaders. You cannot
ention coagulation disorders and not think about Joseph
aprini. Evidence based medicine and not think of Mark
eissner. Venous thromboembolism pathophysiology and
ot think of TomWakefield. Venous stenting and not think
f Seshandri Raju and Peter Neglen. The passion of these
en and others gave venous physicians the respect and
onor they deserve. To me, passion and the AVF are
ynonymous and unseverable terms.
NNOVATION AND INTEGRITY
Improving the care of patients suffering from venous
isease and validating the cognitive and technical skill
ets of venous disease practitioners has been accelerated
y the advent of new technologies. The AVF has thought-
ully and intentionally created a national and international
nvironment that stimulates innovation via its many initia-
ives. The Pacific Vascular Symposia, the CEAP classifica-
ion, physician-validated outcomes tools like the Venous
linical Severity Scoring (VCSS) score, evidenced-based
ractice guidelines, the American Venous Registry, venous
alvular repairs, and the Greenfield Filter are a few examples
f innovations that were developed by the AVF and AVF
eaders. The annual meeting provides a forum for cutting-
dge research presentations and an opportunity to evaluate
he effectiveness of newer technologies. For example, I
istinctly remember the very first presentations on radiofre-
uency ablations that were presented at this meeting. The
echnology was met with great skepticism by the members
f this organization. Our members demanded better clini-
al trials and hard data that could withstand AVF scrutiny.
firmly believe that endothermal ablation techniques
ained national acceptance in part due to the vigilance of
he AVF and the demand by our leadership for clinical
ffectiveness data. Once an analysis of the clinical data we
emanded was available, the AVF adopted this technology
nd actively promoted it.
As I stated previously, endothermal ablative techniques
ere not universally accepted by this organization when
rst introduced. The AVF was criticized by the endother-
al enthusiasts who stated that any and all new techniques
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Volume 54, Number 4 Pappas 1189should be accepted. The enthusiasts felt that lack of accep-
tance would hinder innovation and technological advance-
ment. The AVF resisted such criticism and relied on its core
values for guidance during those tumultuous days. The
AVF has always balanced the need tomove the field forward
with an intense desire to protect patients from the newest
fad of the day. As a result of this balancing act, the AVF has
developed a reputation for integrity and honesty that is
highly valued. Integrity and honesty are key components of
the AVF brand that must be jealously guarded. As a result
of this vigilance, our relationships with industry have been
beyond reproach. My mother often reminded me as a child
that it takes a lifetime to develop a reputation and 5minutes
to lose it. Therefore, our leaders must perpetually remain
vigilant and never jeopardize the organization’s reputation
for any temporary or short-lived gain.
VISION AND LEADERSHIP
Leadership has many forms and definitions. A facet of
leadership is the ability to provide structure and guidance
for an organization and prepare people for future chal-
lenges. Identifying future challenges, assessing environ-
mental circumstances, and convincing people to accept a
shared path is vision. Therefore, leadership and vision are
inseparable components and the lack of one component
diminishes the effectiveness of the other. Leadership and
vision are hallmarks of the AVF. Our founders established
the AVF due to a recognition that the field would not
progress without establishing an organization dedicated to
the entire spectrum of venous diseases. They created an
environment for mentorship, developed future venous dis-
ease advocates, and established the pre-eminent forum for
the exchange of scientific ideas. Twenty-three years later,
the AVF faces new challenges. Varicose vein therapies,
venous stenting, pharmacomechanical thrombectomy de-
vices, improved venous imaging techniques, and diminish-
ing healthcare dollars in nonvenous specialities have in-
creased interest in caring for venous disease patients. It has
been estimated that 80 million people in the United States
have some form of venous disease. Our government and
third-party payers understand the enormity of this patient
population and are beginning to place barriers to venous
healthcare access. For example, Blue Cross and Blue Shield
of Massachusetts recently implemented a coverage policy
stating that only general surgeons, vascular surgeons, and
interventional radiologists will be reimbursed for perform-
ing endothermal ablations due to concerns over patient
safety and the skill set of physicians outside these specialties
performing venous procedures. For example, cardiologists,
dermatologists, internists, gynecologists, family medicine
doctors, wound care centers, and plastic surgeons are all
now interested in performing venous procedures due to
decreasing reimbursement pressures within their own spe-
cialties. The AVF and the American College of Phlebology
(ACP) unsuccessfully fought this coverage policy because
we do not believe insurance companies should determine
local credentialing policies. However, this issue emphasizes
the fact that specialties with little to no formal graduate vedical training in venous disease are caring for venous
isease patients and how ineffectual the AVF and ACPwere
n our initial attempts to influence the policies of a third
arty payer.
ATTLE OF THERMOPOLAE
In response to insurance companies and government
gencies placing restrictions on venous disease healthcare
ccess and as part of thematuration of our organization, the
VF leadership decided in 2007 to add patient and physi-
ian advocacy to our mission. I have thought long and hard
n how to achieve this goal. In searching for an answer, I
ealized that our current situation was not unique and that
he lessons of history can help guide us in our current
ourney. I will therefore take a few moments to share with
ou my vision for the future, how the values I have articu-
ated above and the battle of Thermopolae can show us
ow to proceed.
In the 4th century BC, Greece was a conglomeration of
euding city states with colonies in Asia Minor (today’s
urkey) and Sicily. In 490 BC, Ionia, an Athenian colony in
sia Minor, revolted against the Persian Empire. During
he revolt, Athens assisted Ionia in a losing cause. In
etaliation for the Athenian’s assistance, King Darius of
ersia massed an armada of 600 ships, 20,000 infantry and
avalry, and landed 26 miles north of Athens at Marathon.
utnumbered two to one, the Athenian General Miltiades
sed the Greek terrain to eliminate the Persian’s ability to
se their cavalry and boldly ordered a frontal attack on the
ersian front lines. In the counterattack, the Persians
hought they were pushing the Athenians back against the
ountains. However, the Athenians faked a retreat and
utflanked the Persians. The Persians suffered heavy casu-
lties and retreated to their ships. Although the battle at
arathon was won, the Persian navy was not destroyed.
iltiades ordered a forced march and met the Persians at
thens preventing the destruction of the city. The prevail-
ng wisdom of the day was that Miltiades was a military
enius and the savior of Athens. However, one of Miltia-
es’s generals at Marathon came away with a different
esson. Themistocles realized that the Persian navy almost
aused the destruction of Athens. He realized that infantry
ere only as powerful as their naval support. Themistocles
lso deduced that the Persians would not suffer two defeats
t the hands of the lowly Greeks and that a counterattack
ould eventually come. Themistocles therefore convinced
he Athenian parliament to delegate a portion of the pro-
eeds from a recent silver mine discovery towards building
navy by creating a fake threat from the nearby island of
egina.
Over the next 10 years, Darius directed his efforts at
uashing revolts throughout the empire. To remind him of
he damage the Greeks did to his reputation, he ordered a
ervant to whisper in his ear, every night before dinner,
Sire, remember the Greeks.” Despite quelling the revolts
n his empire, Darius died before he could enact his revenge
n the Greeks. Darius’ son, Xerxes, rose to power and
owed to complete his father’s task. Xerxes amassed the
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engineers constructed a 1-mile bridge across the Bosphorus
Strait rather than travel around the Black Sea and gathered
an army estimated to be as large as 150 to 300,000 strong.
He also gathered 1000 ships to support the infantry and
cavalry. The Athenians learned of the Persian’s plans and
realized they could not stand alone against this enemy. The
Persians meant to destroy Athens and make Greece part of
the Persian Empire. For the first time in Greek history, the
feuding city states put aside their differences, forged an
alliance, and banded together as Greeks. This alliance was
the beginning of Hellenism and set the stage for the even-
tual rise of Alexander the Great many years later. The
Athenians asked King Leonidas of Sparta, the traditional
enemies of the Athenians, to lead the united Greek army
due to their well-known fighting abilities. In return, the
Athenians, under the leadership of Themistocles, provided
200 naval ships for the upcoming battle. History tells us
that once again, the Greeks used Greece’s terrain to
bottleneck the Persian infantry at Thermopolyae’s nar-
row pass and severely damaged the Persian navy in the
narrow Artemesian Straits. The Greeks eventually de-
feated the Persians at Platea and drove them out of
Greece. The second Persian invasion helped Phillip of
Macedon unite Greece and stimulated Alexander the
Great to conquer Persia and prevent them from ever
invading Greece again.
THE FUTURE OF THE AVF
How is any of this relevant to venous disease and the
current healthcare environment we live in today? For most
of my career, I thought the AVF, ACP, SIR, ACCP, and
ASH were the primary organizations that cared about
venous disorders. That notion changed several years ago
when the AVF was asked to join an effort sponsored by the
Vascular Disease Foundation (VDF). The VDF wanted to
create a group called the Venous Disease Coalition (VDC).
The goal of the VDC would be to increase public and
health professional awareness of venous disease. The VDC
was able to get 39 organizations to join their coalition, and
in my opinion, 25 of them have little to no interest in
venous disorders. When I look at a map of where these
organizations have their headquarters, I see Greek city
states. All these organizations are competing for limited
industry and government financial support. Many of these
organizations promote themselves as representing venous
disease patients and purport to be “THE” experts in venous
disease. For many years, many of these organizations have
implemented educational programs, awareness initiatives,
and attempted government outreach all on their own and
in an uncoordinated manner. The AVF was no different.
For many years, we held our own national meeting and for
the most part spoke to our core constituency of Vascular
Surgeons with little effort at outreach. The explosion of
technology and the rise of phlebology as a recognized
American Medical Association specialty has invited many
physicians from various healthcare training backgrounds to
enter the venous world. In my opinion, the AVF has catched many of these events unfold from the sidelines.
lthough we did not obstruct the efforts of other societies,
e were not proactive in offering our own solutions. The
ack of formal training in venous disease principles by
hysicians from nonsurgical or radiologic backgrounds has
aused Blue Cross and Blue Shield of Massachusetts to
uestion the qualifications of venous practitioners. Increas-
ng interest in venous disease by multiple specialties and the
eed to develop uniform standards and qualifications for
enous practitioners was one of many reasons the ACP
reated the American Board of Phlebology. This initiative
as not universally supported by the AVF because graduate
edical education in phlebology is not required for Phle-
ology Board designation and the American Board of
edical Specialists (ABMS) does not recognize the ABPh
s a formal board. Furthermore, as pointed out by Mark
eissner in a debate with Tony Comerota at this meeting
n 2010, it appears unlikely that the ABMS will grant board
r sub-board status to the ABPh, based on their current
riteria.
Based on these events, venous practitioners now face
wo major threats to our specialty. The first threat is a
rowing concern among third-party payers and the govern-
ent over the qualifications of physicians claiming exper-
ise in venous disease. The second threat is a concern
mong these same entities over the exponential growth of
enous procedures performed in the United States. BCBS
f Massachusetts has told the AVF and ACP they have
estricted payment to vascular surgeons, general surgeons,
nd interventional radiologists out of safety concerns and
ave used the lack of uniform training as their justification
espite no evidence that patients have been harmed by
onsurgeons and nonradiologists. This tactic is clearly
eant to restrict access to care and limit the rate of venous
elated payments to physicians. The AVF and ACP jointly
rote letters to BCBS of Massachusetts protesting this
ecision to no avail. It was not long before other states like
isconsin began adopting similar practice restrictions.
To address these threats, I would like to inform this
roup of the steps the AVF has taken on behalf of our
embers and our patients. The first step began 3 years ago
ith a concerted membership drive and becoming a more
nclusive society. To be effective advocates, we need to shed
ur city-state mentality and have more than 300 active
embers. The Executive Council set a goal of 1000 mem-
ers by 2014 and as of today, we have over 600 members
ith 90 new members this year. One thousand members
s large enough to generate operating income yet small
nough to maintain access to our leaders and avoid a
umbersome bureaucracy that inhibits our ability to act and
eact to socioeconomic and political circumstances.
The second step was to implement the lessons taught to
s by Themistocles and Leonidas at Thermopolae. Just as
hemistocles had the wisdom and vision to realize the need
or naval forces and alliances, we must demonstrate the
ame wisdom. Our equivalent of naval forces are our pa-
ients and data. The only weapon that affects insurance
ompanies and government agencies is money, motivated
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Volume 54, Number 4 Pappas 1191voters, and hard medical data. To fortify our professions’
armamentarium, we need to do a better job at generating
real-world, patient-, and physician-derived outcome data
that substantiates the therapies we are performing. At Ther-
mopolae, the Spartans’ superior tactics and better shields
protected them against the poorly crafted arrows of the
Persians and their poorly trained infantry forces. Similarly,
we need better tactics and shields to accomplish our goals.
The AVF’s version of a Spartan shield is the American
Venous Registry. The registry will be the mechanism
whereby we collect real world, patient, and physician gen-
erated data. The American Venous Registry (AVR) is com-
posed of five modules: varicose veins, venous stenting,
pharmacomechanical therapies, vena-caval filters, and up-
per extremity venous thrombosis. As of the beginning of
this meeting, the AVR is now available to any practitioner
that wants to register to us it. The varicose vein module is
up and running. The stent module is being revised, and the
other three modules are in development. The registry has
been prepopulated with data from several high-volume cen-
ters so that new users will be able to perform comparative
effectiveness and outcomes assessments on their patients com-
pared with a national data set. The registry meets the criteria
for an electronic health record, and we are in the process of
having the registry certified. This means that registrants
who utilize the registry will qualify for the 2% Medicare
bonus provided by the government and will satisfy the
government’s requirements that all physicians use Elec-
tronic Health Record in their practice by 2014. A further
benefit is that the registry will satisfy your board’s main-
tainence of certification requirements and has clinical prac-
tice tools that will allow you to generate letters, procedure
notes, and data analyses. Research questions will be gener-
ated through the AVR steering committee or through
requests from registered users. It is our hope that through
the registry, we will gather and publish data on thousands
of patients that will validate the effectiveness of the thera-
pies we are currently providing.
The third step was to reorganize the way the AVF views
fund-raising. The Athenians discovery of a silver mine gave
Themistocles the financial support he needed to build a
navy and prepare his country for the coming invasion. To
become effective advocates and a stronger society, we have
to strengthen our industry relationships, diversify our
sources of funding, and hire professional fund-raisers. My
wife often tells me that if I need my car fixed I will not go to
a surgeon. The time for the AVF to hire professional
fund-raisers has come and the addition of Suzanne Kouri as
our Director of Development has elevated our business
practices and established a model for society/industry part-
nerships worthy of emulation. The corner stone of our
fund-raising efforts is our foundation. The board of direc-
tors of our foundation have worked tirelessly to reorganize
and restructure the foundation in 2010. The foundation
now has the tools it needs to increase our fund-raising
efforts and help the AVF achieve its goals. I look forward to
working with the AVF in the coming years to strengthen
the AVF for future generations. aThe fourth step was to further fortify our armamentar-
um. As Themistocles realized the need for a navy, the AVF
nderstood the need to review the current evidence for
aricose vein treatments and pharmacomechanical thera-
ies. The AVF and SVS jointly performed an analysis of the
urrent literature and developed an evidence-based set of
uidelines that has been accepted for publication by the
ournal of Vascular Surgery. I anticipate these guidelines
ill be published as a supplement to the Journal in the first
r second quarter of 2011. I would like to publicly thank
rs Meissner and Gloviczki and the members of the out-
omes committee for this Herculean effort. By assessing the
urrent evidence and the quality of the data, we have a
etter understanding of where to focus our research efforts.
urthermore, these data can be used as a reference when
alking to your local insurance carriers. This is crucial
ecause insurance companies, to the best of their abilities,
reate medical coverage policies based on their interpreta-
ion of current and existing data. Using these guidelines
nd data from the registry, the AVF and its partners will
each out to local, regional, and national insurance carriers
s well as state insurance commissioners with proposals for
edical coverage policies. State insurance commissioners
ave an annual meeting, and it is my hope that the AVF can
et on their program to discuss our positions and offer our
xpertise.
The fifth step was the creation of an alliance. Leaders
rom the AVF reached out to the ACP and SIR and all three
roups agreed to form an intersocietal committee to ad-
ress government and insurance regulations. Ted King
rom the ACP is the chair of this committee and my version
f King Leonidas. He is very committed to the field of
enous disease, well organized and well respected by all
hree organizations. For the first time in my memory,
eaders from the ACP, AVF, and SIR sat at the same table to
iscuss areas of mutual interest to all three groups. I would
ike to personally thank NickMorrison and JohnMauriello,
ast and current presidents of the ACP, for their partner-
hip, vision, and leadership in this joint venture. The regis-
ry and practice guidelines were made available to the
ommittee and the AVF proposed that all three societies
onsider paying for a full time government relations indi-
idual who will monitor events of importance to the venous
ommunity. The AVF has also formed a government/
nsurance relations committee and named Mike Vasquesz
s the chair. Mike currently sits on the SVS government
elations committee. The SVS government relations com-
ittee is extremely well organized and well respected by
enters for Medicaid and Medicare. This will be a good
raining ground for Mike who will represent the AVF on all
enous-related matters. I also believe that the committee
hould consider contributing to the SVS Political Action
ommittee and that we utilize the SVS lobbyists to pro-
ote venous-related positions in Washington, DC.
The last step was for the AVF to be more proactive in
he issue of board certification for venous practitioners. The
merican Board of Phlebology (ABPh) is now a separate
nd independent entity. There are seven vascular surgeons
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October 20111192 Pappason the ABPh board of directors. Six of them are prominent
AVF members and three are past presidents. It is no coin-
cidence that one-third of the 24 boardmembers are current
or past leaders of the American Venous Forum. The posi-
tions, discussions, and votes that these individuals cast will
be viewed as either implicitly or directly representing the
views of the American Venous Forum. Therefore, I have
reached out to several members of the ABPh board and
shared with them my major concern with the current bo-
ard certification process and issues over the use of the word
“board certification,” In the United States, the term
board certified means that an individual has completed
an Accreditation Council for Graduate Medical Educa-
tion (ACGME)-approved graduate medical education pro-
gram and passed a qualifying and certifying examination. As
you all know, there is no ACGME-approved phlebology
residency and I therefore have a problem with the term
“board certified” in phlebology. I believe this term is
misleading to the general public. I realize that to be eligible
for the ABPh board examination, a candidate can chose one
of four paths that documents how the candidate achieved
graduate medical training in phlebology. Eligibility under
pathway 3 states that a description of your phlebology
training and experience supplied in the form of a letter
written by the applicant, a case log of your last 100 cases,
and three letters from board certified phlebologists, will
qualify an applicant to sit for the examination. I understand
why this pathway exists and what its overall intent is.
However, self-education and self-reporting is no substitute
for a formal graduate medical education training program.
I have therefore instructed Dr Wakefield, one of our past
presidents and a new ABPh board member, to bring these
concerns to the ABPh board and suggested they change the
designation to added qualifications and drop the term
board. In this manner, venous practitioners from nonsurgi-
cal and nonradiological specialties will have some validation
from an outside agency as to their cognitive proficiency and
the beginnings of a mechanism for policing the specialty.
Although this is a good first step, it does nothing to address
the technical skill sets of practicing phlebologists. What can
be done to address technical competency? I want to remind
this group that vascular surgery training programs were not
ACGME approved when they first started out. Training
programs were initiated through the ISCVS/SVS and had
to go through the PEEC approval process in the early days. yven today, transplant surgery is not an approved ACGME
esidency. Transplant programs are regulated through the
ransplant societies and transplant surgery is still considered
primary component of general surgery. I do not believe
hat phlebology has matured enough to be considered for
ub-board status in vascular surgery or radiology. I believe
hat just as in transplant surgery, society-sponsored phle-
ology training programs will slowly develop and the ACP
as in point of fact started this process. These programs
ust focus on developing complete phlebologists and not
ust individuals who specialize in superficial disease. I am
onvinced it is time for the AVF to become part of the
olution to this problem and I have charged the Education
ouncil of the AVF to assist AVF members on the ABPh
oard with the development of graduate medical education
raining curricula. The AVF acknowledges that a wide
ariety of medical specialists are now practicing phlebology.
believe the AVF should create a joint taskforce with the
CP and SIR to address each society’s concerns regarding
he best way to regulate quality of care and to develop a
rocess for regulating the field. I believe all three societies
hould work on defining the specialty and developing mu-
ually agreed upon training curricula. I believe this effort
hould occur concurrently with discussions occurring at the
oard level of the ABPh. Each society now has representa-
ion on the ABPh and we should work together to elevate
nd strengthen the field.
In conclusion, the AVF has achieved the original goals
f our founders. It has been 4 years since the AVF decided
o add patient and physician advocacy to our mission. We
ave made a great start and I hope I have convinced you
ow important your membership and support is. I hope I
ave shown you how hard the AVF leadership is working
n your behalf. I would like to finish this speech with this
ne thought. Before leaving for battle, Spartan women
anded their husband’s or son’s shields to them and spoke
he following words when bidding them farewell, “´H ´
´ ε´´ ´.” Loosely translated, this means “Come back
ictorious or dead on it.” Our specialty and field is under
reat pressure from outside forces. If we do not act in our
wn self-defense, we are at risk for being conquered and
epreciated just as the ancient Greeks were confronted with
ecoming the next conquered peoples of the Persian Em-
ire. ´H ´ ´ ε´´ ´ my friends. ´H ´ ´ ε´´ ´. Thank
ou.
